Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FQSV1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,207
Award facts
- Contract value 100% obligated
- $14,207.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $14,207.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 68 mg Nexplanon implants. The delivery order, issued on December 15, 2025, with an ultimate completion date of January 7, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply the Department of Defense with comprehensive pharmaceutical products and medical consumables to support military healthcare facilities worldwide.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, encompassing a 30-month base period with three 30-month option periods. This structure allows the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic prescription medications, biologics, vaccines, and medical devices to support recurring military medical supply needs globally. DMS Pharmaceutical Group's demonstrated performance across numerous prior delivery orders for specialized pharmaceuticals—including oncology treatments, biologics, vaccines, and contraceptive devices—positions the company as a critical pharmaceutical supplier within the Department of Defense's medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQSV1?
SPE2DR26FQSV1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FQSV1 worth?
The government has obligated $14,207 on SPE2DR26FQSV1.
Is contract SPE2DR26FQSV1 an order under another contract?
Yes. SPE2DR26FQSV1 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQSV1 competed?
The extent of competition for SPE2DR26FQSV1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award